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Abstract
Background: Gene transfer using adeno-associated viral (AAV) vectors has been successfully applied in the retina for the
treatment of inherited retinal dystrophies. Recently, microRNAs have been exploited to fine-tune transgene expression
improving therapeutic outcomes. Here we evaluated the ability of retinal-expressed microRNAs to restrict AAV-mediated
transgene expression to specific retinal cell types that represent the main targets of common inherited blinding conditions.
Methodology/Principal Findings: To this end, we generated AAV2/5 vectors expressing EGFP and containing four tandem
copies of miR-124 or miR-204 complementary sequences in the 39UTR of the transgene expression cassette. These vectors
were administered subretinally to adult C57BL/6 mice and Large White pigs. Our results demonstrate that miR-124 and miR-
204 target sequences can efficiently restrict AAV2/5-mediated transgene expression to retinal pigment epithelium and
photoreceptors, respectively, in mice and pigs. Interestingly, transgene restriction was observed at low vector doses
relevant to therapy.
Conclusions: We conclude that microRNA-mediated regulation of transgene expression can be applied in the retina to
either restrict to a specific cell type the robust expression obtained using ubiquitous promoters or to provide an additional
layer of gene expression regulation when using cell-specific promoters.
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Introduction
MicroRNAs (miRNAs) are a class of small 20–25-nucleotide
long non-coding RNAs that negatively regulate expression of their
target genes by binding to specific sequence elements in the 39
untranslated region (UTR) of their respective mRNAs [1].
MiRNAs predominantly act to decrease target mRNA levels in
animal cells [1] and at least one third of them are expressed in a
cell type- or developmental-specific manner [2]. Only recently,
endogenous miRNAs have been exploited for the tight post-
transcriptional regulation of exogenously delivered (trans)genes in
therapeutic and experimental applications [3]. Incorporation of
target sites for a specific miRNA (miRTs) at the 39 end of a
transgene cassette has been adapted to provide a means of
restricting transgene expression domains to specific cell types,
lineages or differentiation states [4,5,6,7,8]. This strategy is
particularly useful to further improve transgene specificity, when
combined with the transcriptional targeting provided by tissue-
specific promoters. A detailed knowledge of the cellular and
developmental distribution of miRNAs is a major requisite
towards the implementation of this strategy. In one of the first
therapeutic applications of this approach, Brown and colleagues
[9] combined an hepatocyte-specific promoter with target
sequences for a hematopoietic-specific miRNA in a lentiviral-
based vector to abolish the immune response generated by the off-
target expression of clotting factor IX in the antigen-presenting
cells (APCs) of Hemophilia B (DF.IX) mice. The dynamic
expression of miRNAs has also been exploited to ensure an
appropriate restriction of transgene expression across development
[10].
Inherited retinal degenerations (IRDs) are a group of conditions
that result from mutations in genes encoding proteins with critical
functions in retinal pigment epithelium (RPE) or photoreceptor
(PR) cells and lead to severe visual deficits and ultimately to
blindness [11]. IRDs can greatly benefit from gene therapy using
adeno-associated virus (AAV)-derived vectors that transduce non-
dividing cells and result in long-term transgene expression [12].
The safety and efficacy of AAV-based gene therapy has been
verified in various animal models [13] and in humans
[14,15,16,17,18,19,20,21]. Recently, AAV2-mediated gene trans-
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Amaurosis (LCA, type 2; OMIM 204100) achieved stable
improvement of visual and retinal function [14,15,16,17,18,
19,20,21].
Tight spatial and temporal control of transgene expression is
desirable in the context of gene therapy. In IRDs, gene transfer
should be ideally targeted to either RPE or PRs. This can be in
part achieved by selecting the appropriate AAV serotype, as AAVs
show variable kinetics of transgene expression and differential
tropism for a broad range of ocular cell types [22]. Specificity of
transgene expression in the retina can be further enhanced using
RPE- or photoreceptor-specific promoter elements [23,24].
However, very often the tissue-specific promoters used in gene
therapy vectors do not faithfully recapitulate the patterns of the
endogenous promoter. In addition, the levels of transgene
expression obtained may either be inadequate for therapeutic
purposes or supra-physiological and deleterious for retinal
function.
With this study, we aimed to improve controlled transgene
expression in the retina by exploiting the post-transcriptional
regulation offered by the endogenous miRNA machinery. To this
end, we integrated our knowledge on the cellular distribution of
miRNAs within the mouse eye [25,26] with the use AAV-
mediated strategies for gene transfer to the retina [22]. Here we
describe the first paradigm of harnessing retinal-specific miRNAs
to delimit transgene expression to the RPE monolayer or the PRs
of the adult retina using AAV vectors. We show that efficient
restriction of transgene expression can be obtained even at low
vector dosages. These findings have implications for the design of
gene therapy approaches for hereditary retinopathies as they may
improve safety and efficacy of gene transfer.
Results
Use of miR-204 target sites restricts transgene expression
to murine PRs in vivo
We sought to assess whether post-transcriptional restriction of
AAV-mediated transgene expression to PRs could be achieved by
exploiting endogenous miRNAs. For this purpose we selected
miR-204, a miRNA that is strongly expressed in the RPE from as
early as E10.5 to adulthood [25,26] (Figure 1a). miR-204
expression was absent from the PRs and was detected by in situ
hybridization (ISH) at low levels in the inner nuclear layer of the
neural retina as well in the ganglion cell layer [26] (Figure 1a).
Based on the miR-204 expression pattern in the adult murine
retina, we inserted four copies of a sequence that is perfectly
complementary to the mature miR-204 (miR204T) immediately
downstream of the Woodchuck hepatitis virus Post-transcriptional
Regulatory Element (WPRE) in the pAAV2.1-CMV-EGFP
plasmid (Figure 1b; see Materials and Methods). The presence
in this plasmid of the ubiquitous CMV promoter drives robust
transgene expression in both RPE and PRs [27,28]. The resulting
pAAV2.1-CMV-EGFP-4xmiR204T plasmid (Figure 1b) was
used to produce AAV2/5 vectors that efficiently transduce RPE
and PRs upon subretinal administration in several species,
including mice [29]. Four-week-old C57BL/6 mice (n=4) were
injected with 2.6610
9 genome copies (GC) (defined as ‘‘high
dose’’) of AAV2/5-CMV-EGFP-4xmiR204T in one eye, and the
same dose of AAV2/5-CMV-EGFP as control in the contralateral
one. Four weeks after injection, eyes were harvested, retinas were
sectioned and retinal sections were analyzed by direct fluorescence
microscopy to assess localization of EGFP expression.
The number of EGFP-positive RPE cells in the eyes injected
with AAV2/5-CMV-EGFP-4xmiR204T (Figures 2c,d) was
dramatically reduced, compared to contralateral eyes injected
with AAV2/5-CMV-EGFP (Figures 2a,b), indicating efficient
suppression of the EGFP-miR204T mRNA by endogenous miR-
204. Despite the strong reduction of EGFP expression in the RPE,
occasional EGFP-positive RPE cells were detected (red arrows in
Figures 2c,d). We hypothesized that loss of miR-204-mediated
regulation in these EGFP-positive RPE cells could result from the
saturation of the miRNA activity due to an excess of exogenous
miR204Ts. To indirectly test this, we used a 10-fold lower vector
dose (2.6610
8 GC/eye; defined as ‘‘low dose’’). Analysis of EGFP
fluorescence in the low-dose group (n=4) showed specific
restriction of transgene expression to the PRs, while no EGFP
expression could be detected within the RPE in any of the sections
from the four eyes injected with the miR204T-containing vector
(Figures 2e,f).
Use of miR-124 target sites restricts transgene expression
to murine RPE in vivo
To restrict AAV2/5-CMV-mediated transgene expression to
the RPE, we exploited miR-124, a miRNA abundantly expressed
in differentiated neurons [30]. We and others have shown by ISH
that miR-124 stains strongly all retinal cell layers, but is not
detected in the RPE [26,31] (Figure 1a). Therefore, we cloned
four tandem copies of a sequence that is perfectly complementary
to the mature miR-124 downstream of the WPRE element in the
pAAV2.1-CMV-EGFP plasmid (Figure 1b). The resulting
pAAV2.1-CMV-EGFP-4xmiR124T plasmid was used to produce
AAV2/5 vectors that were administered to C57BL/6 mice by
subretinal injection. Mice (n=4) received 2.6610
9 GC (defined as
‘‘high dose’’) of AAV2/5-CMV-EGFP-4xmiR124T in one eye,
and the same dose of the AAV2/5-CMV-EGFP as control in the
contralateral one. The animals were sacrificed four weeks after
injection. Reporter expression in the transduced retina was
evaluated by fluorescence microscopy of retinal sections.
We observed a dramatic reduction in the number of EGFP-
positive PRs in eyes injected with the AAV2/5-CMV-EGFP-
4xmiR124T (Figures 2g,h) compared to eyes injected with the
control vector (Figures 2a,b), suggesting efficient elimination of
the miRT-containing transcript by the endogenous miR-124.
However, similarly to what observed with the miR204T-
containing construct, few scattered EGFP-positive PR cells could
be seen in the neural retina (red arrows in Figures 2g,h), which
implies loss of miRNA-mediated regulation therein. EGFP
expression in these cells could result from the saturation of
miRNA activity due to an excess of exogenously provided
miR124Ts. We then tested a 10-fold decrement in vector dose
to assess if off-target expression of the miRT-containing transcript
in the transduced PRs would be eliminated. C57BL/6 mice (n=4)
were injected with 2.6610
8 GC/eye of either virus, and their eyes
were analyzed four weeks after injection. We did not observe any
EGFP-positive cells in the neural retina of eyes administered with
the low dose of AAV2/5-CMV-EGFP-4xmiR124T (Figures 2i,j),
suggesting that at this dose, the presence of the miR124Ts tightly
restricts transgene expression to the RPE.
Finally, to exclude that the presence of exogenous miRNA
target sequences can interfere with the physiological function of
the PRs, we performed electroretinograms (ERG) on mice injected
at a high dose (2.6610
9 GC/eye) with the AAV2/5 vectors
harboring the miR-124 or miR-204 target sequences and the
control EGFP construct. ERG recordings of eyes injected with the
miRT-bearing vectors showed no statistically significant differenc-
es compared to eyes injected with the EGFP control [max a-wave
amplitude: EGFP=336,18 mV( 667,06); miR124T=350,97
(6132,11) mV; miR204T=320,70 (6105,09) mV; max b-wave
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(690,28) mV; miR204T=690,83 (6143,96) mV].
miRNA-regulation of transgene expression in the porcine
retina
We extended our studies to the pig (Sus scrofa) as, among non-
primate mammals, the porcine retina most closely resembles the
human one in terms of size, anatomy, cellular composition and
physiology, rendering it a valuable preclinical model system for eye
disease and therapy [32]. The mature sequence of miR-124 and
miR-204 is identical in pigs and mouse (miRBase, http://www.
mirbase.org/; [33]). Given the highly conserved cellular distribu-
tion of these two miRNAs across species [26,34,35], we assumed
that miR-124 and miR-204 are likely to be expressed in the same
porcine retinal layers.
We injected subretinally eleven week-old Large White (LW)
female pigs (n=2 eyes/group) with AAV2/5-CMV-EGFP-
4xmiR204T and AAV2/5-CMV-EGFP-4xmiR124T and com-
pared them with eyes injected with the AAV2/5-CMV-EGFP as
control. Considering the size proportions of murine and porcine
eyes, the dose administered in pigs was equivalent to the low dose
injected in mouse (in the mouse eye we administered 1 ml
containing 2.6610
8 GC, in the pig eye 100 ml of a 1:2.6 dilution
of the same vector solution, thus containing 1610
10 GC). Retinal
sections were analyzed, following animal sacrifice six weeks after
injection. As shown in Figure 3, the use of target sequences for
miR-204 (Figures 3c,d) and miR-124 (Figures 3e,f) efficiently
restricted AAV2/5 mediated EGFP expression to the PRs and
RPE of the porcine retina, respectively.
Cones are important targets of gene therapy since several
blinding conditions, either inherited as monogenic or as complex
traits, are due to mutations in genes expressed in cones or are
characterized by progressive cone degeneration [36]. Since the
porcine retina has a high number of cones compared to the
murine one [37], we checked whether both rod and cone PRs
were equally transduced following AAV2/5-mediated delivery.
Expression of EGFP in cone PRs was confirmed by immunolabel-
ling of porcine retinal sections with the Cone Arrestin antibody
Figure 1. miR-124 and miR-204 expression in retina supports the use of AAV vectors harboring corresponding miRTs. (a) Expression
profile of miR-204 and miR-124 in retina sections of adult, albino (CD1) mouse as revealed by ISH using LNA-modified probes. miR-124, a neuronal-
specific miRNA, is expressed in all layers of the neural retina but is not detected in the RPE. miR-204 is expressed in the GCL and the INL of the neural
retina and stains strongly the RPE. RNA ISH for the detection of mature miRNAs was performed using miRCURY LNA
TM microRNA Detection Probes
(Exiqon, Vedbaek, Denmark) as previously described [26]. (b) Schematic representation of the AAV vectors harboring the miRT sites. Four tandem
copies (4xmiRT) of a sequence perfectly complementary to the sequence of the mature miR-124 or miR-204 (see alignments) were cloned
downstream of the WPRE element in the pAAV2.1-CMV-EGFP plasmid. Abbreviations are as follows: CMV, Human Cytomegalovirus promoter; EGFP,
Enhanced Green Fluorescence Protein; GCL, Ganglion Cell Layer; INL, Inner Nuclear Layer; IPL, Inner Plexiform Layer; ITR, Inverted Terminal Repeat;
miRT, miRNA target site; ONL, Photoreceptor Outer Nuclear Layer; OS, Photoreceptor Outer Segments; RPE, Retinal Pigment Epithelium; WPRE,
Woodchuck hepatitis virus Post-transcriptional Regulatory Element.
doi:10.1371/journal.pone.0022166.g001
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PLoS ONE | www.plosone.org 4 July 2011 | Volume 6 | Issue 7 | e22166Figure 3. miRNA-regulated EGFP expression in the pig retina. Large White (LW) female pigs (n=2 eyes/group) were injected subretinally with:
AAV2/5-CMV-EGFP (a and b); AAV2/5-CMV-EGFP-4xmiR204T (c and d); AAV2/5-CMV-EGFP-4xmiR124T (e and f). All eyes were injected with
1610
10 GC/eye of each vector. Retinal cryosections were obtained six weeks after injection and analyzed by direct fluorescence microscopy.
Magnification 10X (a–c) and 40X (d–f). Scale bar=100 mm. For abbreviations, see Fig. 2 legend.
doi:10.1371/journal.pone.0022166.g003
Figure 2. miRNA-regulated EGFP expression in the mouse retina. C57BL/6 adult mice (n=4 eyes/group) were injected subretinally with:
2.6610
9 GC/eye of AAV2/5-CMV-EGFP (a and b; high dose); 2.6610
9 GC/eye (c and d; high dose) or 2.6610
8 GC/eye (e and f; low dose) of AAV2/5-
CMV-EGFP-4xmiR204T; 2.6610
9 GC/eye (g and h; high dose) or 2.6610
8 GC/eye (i and j; low dose) of AAV2/5-CMV-EGFP-4xmiR124T. Mice were
sacrificed four weeks after injection, and retinal sections were analyzed by direct fluorescence microscopy. Images at 10X (panels on the left) and 40X
magnification (panels on the right) are shown. At high vector doses ectopic EGFP expression (red arrows) was observed in few PR and RPE cells,
respectively. Scale bar=100 mm. Abbreviations: RPE, retinal pigment epithelium; ONL, photoreceptor outer nuclear layer; INL, inner nuclear layer;
GCL, ganglion cell layer.
doi:10.1371/journal.pone.0022166.g002
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detected by confocal microscopy in the PRs of eyes injected with
the AAV2/5-CMV-EGFP-4xmiR124T (Figure 4c).
With the prospect of using this strategy in animal models of
inherited retinal degeneration, we included target sequences for
miR-204 in an AAV vector encoding the human AIPL1 gene,
mutated in LCA type 4 (OMIM 604393), with the aim to
efficiently transfer AIPL1 to PRs, its main expression site in the
retina. We have recently shown that AAV2/8 vectors target
murine [27] and porcine PRs [38] more efficiently than AAV2/5.
Therefore, we generated an AAV2/8-CMV-hAIPL1-4xmiR204T
vector. The AAV2/8-CMV-hAIPL1-4xmiR204T vector was
injected subretinally in two eleven week-old Large White (LW)
female pigs along with the control AAV2/8-CMV-hAIPL1 that
lacks the miR-204 target sites in the contralateral eye. The animals
were sacrificed six weeks after injection and their eyes were
harvested. Retinal cryosections were then analyzed by immuno-
fluorescence with antibodies directed to human, but not porcine,
AIPL1 using confocal microscopy. Transgene expression was
detected in both PRs and RPE of the porcine retinas injected with
the AAV2/8-CMV-hAIPL1 control vector, while hAIPL1 expres-
sion was efficiently restricted to the PRs in retinas injected with the
miR204-regulated vector (Figure 5).
To assess whether the presence of miRNA target sequences
perturbs normal retinal function, ERG recordings were performed
on all injected pigs. Both rod and cone isolated and combined
Figure 4. Cone transduction following subretinal administration of AAV vectors bearing miRNA target sites. Retinal cryosections from
animals injected subretinally with the various miRNA-regulated vectors as in Fig. 3 were immunolabelled with the cone-specific anti-Cone Arrestin
(CAR) antibody (red label). Representative sections of eyes injected with AV2/5-CMV-EGFP (a), AAV2/5-CMV-EGFP-4xmiR204T (b) and AAV2/5-CMV-
EGFP-4xmiR124T (c). Colocalization of EGFP and CAR expression is indicated by the arrows. Confocal microscope magnification 63X. Scale
bar=10 mm. For abbreviations, see Fig. 2 legend.
doi:10.1371/journal.pone.0022166.g004
Figure 5. miR204-regulated expression of hAIPL1 is restricted to the porcine photoreceptors. LW pigs were injected with 1610
10 GC/eye
with AAV2/8-CMV-hAIPL1 (a) and AAV2/8-CMV-hAIPL1-4xmiR204T (b) (n=2 eyes/group). Human AIPL1 immunostaining (red) was performed on pig
retinal sections to assess the localization of the transgene expression. The antibody used does not cross-react with the porcine Aipl1. An over-
exposure of the section in panel (b) is shown in (c) to highlight that no hAIPL1 expression was detected in the RPE cells of eyes injected with AAV2/8-
CMV-hAIPL1-4xmiR204T. Confocal microscope magnification 63X. Scale bar=10 mm. For abbreviations, see Fig. 2 legend.
doi:10.1371/journal.pone.0022166.g005
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significant differences compared to baseline measurements [base-
line pre-treatment, photopic=120 (64,86) mV; scotopic=44,7
(60,5) mV and maximal response 196,6 (69,21) mV; post-
treatment, photopic=130,5 (65,5) mV; scotopic=48 (62,5) mV
and maximal 202 (65) mV] indicating normal retinal function in
the injected animals.
Subretinal administrations of AAV vectors harboring
miRNA target sites do not significantly perturb
endogenous miRNA activity in the eye
As described before, we detected some scattered and discontin-
uous EGFP-positive areas within the RPE and PR layers (red
arrows in Figures 2c,d,g,h) of murine retinas injected with high
doses (2.6610
9 GC/eye) of AAV2/5-CMV-EGFP-4xmiR204T
and AAV2/5-CMV-EGFP-4xmiR124T, respectively. We hypoth-
esized that endogenous miRNAs did not completely eliminate the
miRT-bearing EGFP transcripts, thus resulting in unexpected
EGFP expression. This could be due to miRNA saturation (i.e.
depletion of levels of the corresponding endogenous miRNA)
caused by the presence of an excessive number of exogenously
provided miRNA binding sites. Alternatively, the high number of
vector-borne miRTs may have elicited a general deregulation of
the miRNA/RISC machinery, resulting in a compromised
repressive function. When mice were injected with the same
vectors at lower doses, we did not detect any ectopic EGFP
fluorescence (Figures 2e,f,i,j), suggesting that off-target trans-
gene expression was a dosage-dependent phenomenon.
To assess whether expression of exogenous sequences carrying
miRTs could interfere with the normal function of the miRNA
machinery, we analyzed the endogenous levels of the correspond-
ing miRNAs by qRT-PCR. In particular, we analyzed the
expression levels of miR-204 and miR-124, as well as of miR-
182. The latter is strongly expressed in the neural retina,
predominantly in PRs [25,26], and, to our current knowledge, is
unlikely to either be under the direct control of any of the miRNAs
tested or have affinity for the miR-204 and miR-124 miRTs. We
extracted total RNA either from retinas of AAV2/5-CMV-EGFP-
4xmiR124T injected mice (n=4; high dose group) or from the
optic cups (including retina, RPE and sclera) of animals injected
with AAV2/5-CMV-EGFP-4xmiR204T (n=4; high dose group).
As miR-204 is mainly expressed in the RPE and off-target EGFP
expression was detected therein, we reasoned that any potential
saturation of miR-204 should be assessed in samples that include
RPE. We did not observe any significant variation in the
endogenous levels of the miRNAs analyzed (Figure S1a),
implying the absence of a detectable miRNA saturation effect at
the level of the whole retinas or optic cups.
To check whether the high number of miRTs could perturb the
capacity of miRNAs to regulate their physiological target genes,
we analyzed the expression levels of VAMP3 and RDH10, two
direct targets of miR-124 [39,40] in retinal samples of animals
(n=4) injected with high doses of either the control AAV2/5-
CMV-EGFP or the construct bearing the miR-124 binding sites.
VAMP3, also known as cellubrevin, is a member of the vesicle-
associated membrane protein (VAMP)/synaptobrevin family [41]
and is strongly expressed in the retina, according to the BioGPS
gene annotation portal (http://biogps.gnf.org/). On the other
hand, RDH10 encodes for retinol dehydrogenase 10 (all-trans) and
is primarily expressed in the RPE and the neural retina
[42](Mouse Retina SAGE library; [43]). We did not detect any
significant variation in the endogenous levels of these target genes
(Figure S1b), suggesting that the AAV-borne miR124Ts do not
interfere with normal miRNA function. Taken together, the above
results imply that the exogenously supplied miRTs do not saturate
endogenous miRNA levels nor alleviate miRNA repression from
its natural targets.
Discussion
Recently, miRNA-mediated regulation of transgene expression
has been successfully achieved in the context of somatic gene
transfer in specific cell types, lineages or developmental stages [3].
In the present study, we show for the first time that this strategy
can be applied to the retina. Subretinal administration of AAV2/5
results in optimal RPE transduction, but also in robust transgene
expression in PRs [22]. Here, we demonstrate that subretinal
administration of AAV2/5 vectors containing expression cassettes
harboring binding sites for miRNAs expressed in specific retinal
cell types results in transgene expression tightly restricted to either
the RPE or PRs of mice and pigs. In particular, constructs
harboring miR-124 binding sites can efficiently de-target reporter
expression from the PRs, while the presence of miR-204 sites
induces elimination of transgene expression from the RPE. The
validation of this approach in the porcine retina confirmed its high
clinical potential.
The use of miRNA-regulated vectors can be advantageous in
gene therapy for inherited eye diseases: in one instance, when
coupled to cell-specific promoters, it adds a layer of regulation to
transgene expression. This is desirable as often the promoter
elements used in gene therapy vectors do not faithfully recapitulate
the expression patterns of the endogenous promoter, probably due
to the absence of distant, secondary regulatory elements [9]. For
instance, the promoter of Rhodopsin - a gene strongly and specifically
expressed in rod PRs- induces aberrant reporter expression also in
cones [27,44]. In addition, the levels of transgene expression
obtained using tissue-specific promoters may not be adequate. For
instance, the Rhodopsin promoter drives very robust gene expression
in PRs. This is not surprising since rhodopsin accounts for more
than 70% of PR proteins [45]. While the Rhodopsin promoter
element maybe desirableif one wantsto replaceorrepress Rhodopsin
expression, the levels of expression of other transgenes may be
supra-physiological or toxic. On the other hand, other retinal-
specific promoters, like RPE65 [23] or OA1 [46], may provide
subtherapeutic levels of transgene expression for some applications
in the RPE. Indeed, in one LCA2 clinical trial (ClinicalTrials.gov
number,NCT00516477),we haveused AAV2/2 vectorsexpressing
RPE65 from the robust constitutive CBA promoter to obtain
therapeutic levels of trangene expression. Assuming that the CBA
expression pattern following subretinal administration of AAV2/2
vectors in the human retina is similar to that observed in mice and
dogs [47,48], we arepresumably misexpressing the RPE65 inPRsin
addition to the RPE. Although this does not appear to be a problem
as we did not observe any retinal toxic effect so far [21], ideally we
could have tailored RPE65 expression to RPE if we had included
miR-124 target sites in our AAV vector.
A main concern for the application of miRNA-regulated
transgene delivery is the potential to saturate their cognate miRNA
by exogenously provided miRTs, thus reducing its bioavailability
and alleviating control of its natural targets. Interestingly, in all
studies that have employed lentiviral platforms for the delivery of
miRNA-regulated transgenes, there is no evidence that the excess of
exogenously provided miRTs - when engineered according to the
principles set for regulated targets [3] - saturates the cognate
miRNA [3,4,5,6,9]. Gentner and colleagues showed that only when
expression isdrivenbyverystrongpromoters orwhenseveralvector
copies are introduced, transgene constructs containing four copies
of perfectly complementary miRTs are able to saturate miRNA
MicroRNAs and Retinal Gene Transfer
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designed our vectors according to the principles set for regulated
targets to prevent miRNA inhibition in the presence of a strong
CMV promoter [3]. Indeed, most of the studies applying these
parameters report no evidence of miRNA saturation [3]. We
observed some scattered, off-target EGFP expression in murine
retinas injected with high doses of miRT-bearing vectors, indicative
of miRNA inhibition which was not detected when using a ten-fold
lower AAV vector dose. However, we did not measure altered levels
of neither miRNAs nor their target genes in the retinas treated with
high AAV vector doses suggesting that miRNA saturation, if
present, occurs at levels below the detection limit of our assay. As an
alternative to lowering the dose of viral genome copies adminis-
tered, the number of miRTs present in the vector constructcould be
reduced.
The PR- and RPE-restricted pattern of transgene expression at
low vector doses was confirmed in the pig retina, which is more
similar to the human one in terms of size and anatomy [32]. We
can thus expect that a dose similar to the one successfully used in
pigs could be applied to humans. Indeed, we have used a similar
dose (1.5610
10 GC/eye) of AAV2/2 in patients with LCA2
obtaining improvement of visual function [19,20,21]. Our data
suggest that administration of low doses of miRT-harboring
vectors enables to tailor transgene expression to specific retinal cell
types in the absence of off-target effects and deregulation of
endogenous miRNA activity.
Ultimately, the efficacy of AAV-mediated miRNA-regulated
gene expression in the retina should be proven in animal models of
IRDs and, ideally, in non-human primates which possess a cone-
enriched macula. Our data suggest that the addition of miRNA
target sites to gene therapy vectors enables fine-tuning of transgene
expression in the retina possibly rendering gene therapy safer and
more efficient.
Materials and Methods
Plasmid construction, AAV vector production and
purification
Recombinant AAV vectors containing the EGFP cDNA under
the cytomegalovirus (CMV) promoter and four copies of a
sequence (referred to as ‘miRT’) that is perfectly complementary
to the miRNAs of interest in the 39 UTR were constructed by a
two-step cloning protocol. Initially, the cassette containing four
copies of a sequence which is perfectly complementary to miR-204
(in capital letters) was constructed by annealing the following two
sets of oligonucleotides: 59-ctagatctAGGCATAGGATGACAAA-
GGGAAcgataggcatAGGATGACAAAGGGAAaagctt-39,5 9-TT-
CCCTTTGTCATCCTATGCCTatcgTTCCCTTTGTCATCC-
TATGCCTAGAT-39 and 59-AGGCATAGGATGACAAAGG-
GAAtcacAGGCATAGGATGACAAAGGGAAagatc-39,5 9-tcgagatct-
TCCCTTTGTCATCCTATGCCTgtgaTTCCCTTTGTCATCCT-
ATGCCTaagctt-39.
Similarly, the cassette containing four copies of a sequence
which is perfectly complementary to miR-124 (in capital letters)
was constructed by annealing the following two sets of oligonu-
cleotides:
59-ctagatctGGCATTCACCGCGTGCCTTAcgatGGCATTC-
ACCGCGTGCCTTAaagctt-39,5 9-TAAGGCACGCGGTGAA-
TGCCatcgTAAGGCACGCGGTGAATGCCagat-39 and 9-GG-
CATTCACCGCGTGCCTTAtcacGGCATTCACCGCGTGC-
CTTAagatc-395, 59-tcgagatctTAAGGCACGCGGTGAATGCC-
gtgaTAAGGCACGCGGTGAATGCCaagctt-39. In either case,
the resulting double-stranded fragments (each one containing two
copies of the respective miRT) were ligated thanks to the presence
of phosphorylated 59 ends. The obtained fragments (containing
four copies of the respective miRT) were subcloned in pBluescript
II SK(+) previously digested with Xba I and Xho I. The recombinant
clones were digested with Bgl II to release the fragment containing
the four miRT sites with Bgl II protruding ends. The fragment was
then cloned into the Bgl II site of the pAAV2.1-CMV-EGFP
plasmid [27] and used for the production of AAV2/5 vectors.
To generate the vectors expressing hAIPL1, the coding sequence
of the hAIPL1 gene was amplified from human retina cDNA
(BioChain, Hayward, CA) using the primers hAIPL1-NotI-
forward (59-ATATGCGGCCGCCATGGATGCCGCTCTGC-
TCCT- 39) and hAIPL1-HindIII-reverse (59- ACGCGTAAGC-
TTTTATCAGTGCTGCAGCGAGTGCC- 39) and cloned into
the pAAV2.1-CMV-EGFP following digestion with Not I and Hind
III. The final pAAV2.1-CMV-hAIPL1-4xmiR204T plasmid was
subsequently produced by cloning the fragment containing four
miR-204 target sites (released by Bgl II digestion of the pAAV2.1-
CMV-EGFP-4xmiR204T) in the Bgl II site of pAAV2.1-CMV-
hAIPL1.
AAV vectors were produced by triple transfection of 293 cells,
purified by two rounds of CsCl2 ultracentrifugation, and titered (in
GC/milliliter) using a real-time PCR-based assay TaqManH
(Applied Biosystems, Foster City, CA) and a dot-blot analysis, as
previously described [28]. AAV vector production was carried out
by the TIGEM AAV vector core.
Animal procedures and vector administration
Ethics Statement. All studies on mice were conducted in
strict accordance with the institutional guidelines for animal
research and with the Association for Research in Vision and
Ophthalmology (ARVO) Statement for the Use of Animal in
Ophthalmic and Vision Research. All animal treatments were
reviewed and approved in advance by the Ethics Committee of the
Centre of Biotechnology, Animal Research Unit, Cardarelli
Hospital (Naples, Italy). All procedures on mice were then
approved by the Italian Ministry of Health (protocol number:
0000667/11/CB; approval date Sept. 11, 2007).
The experiments involving pigs were conducted according to
relevant national and international guidelines. All procedures on
pigs were reviewed and approved in advance by the Ethics
Committee of the Department of Veterinary Medical Science,
University of Bologna (Bologna, Italy) and were then approved by
the Italian Ministry of Health (protocol number: 23/2009-B,
approval date Feb. 04, 2009). All surgery was performed under
anesthesia, and all efforts were made to minimize suffering.
Mice. Four-week old C57BL/6 mice (Harlan, S. Pietro al
Natisone, Italy) were anesthetized with an intraperitoneal injection
of avertin (1.25% w/v of 2,2,2-tribromoethanol and 2.5% v/v of
2-methyl-2-Butanol; Sigma–Aldrich, St. Louis, MO) at 2 ml/
100 g of body weight, and viral vectors were delivered via a trans-
scleral transchoroidal approach, as previously described [50]. Mice
were injected in the right eye with 2.6610
9 GC of AAV2/5-
CMV-EGFP-4xmiRT in the high dose experiments and
2.6610
8 GC of AAV2/5-CMV-EGFP-4xmiRT in the low dose.
The same doses of AAV2/5-CMV-EGFP were injected in the left
eye, as control. Following injection, the extent of transduction was
assessed by ophthalmoscopy at days 7 and 28. Eyes were harvested
at day 28 after injection.
Pigs. The Large White pigs (LW) used in our study were
registered as purebred in the LW Herd Book of the Italian
National Pig Breeders’ Association. Pigs were starved overnight
leaving water ad libitum. The anesthetic and surgical procedures for
pigs were previously described [38].
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Mice were sacrificed, and their eyeballs were then harvested
and fixed overnight by immersion in 4% paraformaldehyde
(PFA). Before harvesting the eyeballs, the temporal aspect of the
sclerae was marked by cautery in order to orient the eyes with
respect to the injection site at the moment of the inclusion. The
eyeballs were cut so that the lens and vitreous could be removed
leaving the eyecup intact. Mice eyecups were infiltrated with 30%
sucrose for cryopreservation, and embedded in tissue freezing
medium (O.C.T. matrix, Kaltek, Padua, Italy). For each eye, 150
to 200 serial sections (10 mm-thick) were cut along the horizontal
plane and the sections were progressively distributed on 10 slides
so that each slide contained 15 to 20 sections, each representative
of the whole eye at different levels. The sections were stained with
49,69-diamidino-2-phenylindole (Vectashield, Vector Lab Inc.,
Peterborough, UK) and EGFP was monitored with a Zeiss
Axiocam (Carl Zeiss, Oberkochen, Germany) at different
magnifications.
Pigs were sacrificed and their eyeballs were harvested and fixed
overnight by immersion in 4% PFA. The eyeballs were cut so that
the lens and vitreous could be removed, leaving the eyecups in
place. The eyecups were cryoprotected by progressive infiltration
with 10%, 20% and 30% sucrose. Before embedding, the swine
eyecups were analyzed under a fluorescence stereomicroscope
(Leica Microsystems GmbH, Wetzlar, Germany) in order to
localize the transduced region, whenever an EGFP-encoding
vector was administered. Embedding was performed in tissue-
freezing medium (O.C.T. matrix, Kaltek, Padua, Italy). For each
eye, 200 to 300 serial sections (12 mm-thick) were cut along the
horizontal meridian and the sections were progressively distributed
on glass slides so that each slide contained 6 to 10 sections. Section
staining and image acquisition was performed as described for
mice.
Immunofluorescence staining
Frozen retinal sections were washed once with PBS and then
fixed for 10 min in 4% PFA. Sections were then permeabilized for
1 hour in PBS containing 0.1% TritonH X-100. Blocking solution
containing 10% normal goat serum (Sigma–Aldrich, St. Louis,
MO) was applied for 1 hour. Primary antibodies were diluted in
PBS and incubated overnight at 4uC. The secondary antibody
(Alexa FluorH 594, anti-rabbit, 1:1000; Molecular Probes,
Invitrogen, Carlsbad, CA) was incubated for 45 min. The primary
antibodies used were rabbit anti-hAIPL1 (1:700; kindly provided
by Michael E. Cheetham, University College London, London,
UK) and rabbit anti-hCAR [51] (1:10000; kindly provided by
Cheryl M. Craft, University of Southern California, Los Angeles,
Ca). Vectashield (Vector Lab Inc., Peterborough, UK) was used to
visualize nuclei. Sections were photographed using either a Zeiss
Axioplan microscope (Carl Zeiss, Oberkochen, Germany) or a
Leica Laser Confocal Microscope System (Leica Microsystems
GmbH, Wetzlar, Germany).
Electroretinography
Electrophysiological recordings in mice were performed as
detailed in [52] and bilateral ERG evaluations in pigs were carried
out as previously described [38].
miRNA and gene expression analysis
MiRNA and gene expression analysis in mice administered with
the AAV2/5-CMV-EGFP-4xmiR124T and AAV2/5-CMV-
EGFP-4xmiR204T constructs was performed on samples from
whole retinas and optic cups, respectively. Total RNA was
extracted using the miRNeasy kit (Qiagen, Inc., Hilden, Germany)
according to the manufacturer’s instructions and quantified using
the NanoDrop 1000 (Thermo Fischer Scientific, Waltham, MA).
RNA quality was assessed by gel electrophoresis.
Quantitative (q) Reverse Transcriptase (RT-) PCR-based
detection of mature miR-124, miR-182 and miR-204 was
performed using the TaqManH microRNA assays (Applied
Biosystems, Foster City, CA). All reactions were performed in
triplicate. The qRT-PCR results, recorded as threshold cycle
numbers (Ct), were converted to absolute copy number (i.e. copies
of miRNA per ng of RNA) using a standard curve. To generate
the standard curve, serial amounts (ranging from 10
2 to 10
8 copies)
of a synthetic RNA oligonucleotide corresponding to miR-124 (59-
UAAGGCACGCGGUGAAUGCC-39; Sigma–Aldrich, St. Louis,
MO) were mixed with 10 ng of total yeast RNA. The samples
were analyzed using the TaqManH microRNA assay and the
correlation between threshold cycle numbers (Ct) and copies of
miRNA was established.
For the expression analysis of target genes, cDNA synthesis was
performed using the Quantitect Reverse Transcription kit
(Qiagen, Inc., Hilden, Germany) starting from 1 mg of DNase-
treated RNA. In order to unambiguously distinguish spliced
cDNA from genomic DNA contamination, exon-specific primers
were designed to amplify across introns of the genes tested. All
primers were previously tested by reverse transcription (RT)-PCR
and no RT control reactions were performed. Primer sequences
are the following: MmRdh10_For: 59-CTAGAGATTAAT-
CATGGCCAC-39; MmRdh10_Rev: 59-CTCGTGAAAACCCA-
CAACTC-39; MmVamp3_For: 59-CAGACACAAAATCAAG-
TAGATG-39; MmVamp3_Rev: 59-CAGTGCATCTGCGCGG-
TC-39. qRT-PCR experiments were performed using the ABI
Prism 7900HT Fast Sequence Detection System with ABI Power
SYBR Green reagents (Applied Biosystems, Foster City, CA).
Real-time PCR results were analyzed using the comparative Ct
method normalized against the housekeeping genes GAPDH and
ACTB. The range of expression levels was determined by
calculating the standard deviation of the DCT.
Supporting Information
Figure S1 AAV vectors harboring miRTs do not detec-
tably perturb miRNA expression and activity in the eye.
(a) miRNA expression profile analysis in retinas and optic cups of
animals injected subretinally with AAV (n=4 samples/group).
Expression levels were determined by qRT-PCR on RNA
extracted from retinas injected with AAV2/5-CMV-EGFP-
4xmR124T and from optic cups of eyes treated with AAV2/5-
CMV-EGFP-4xmR204T following delivery of a high AAV vector
dose (2.6610
9 GC/eye). Subretinal administration of AAV vectors
harboring miRTs does not detectably perturb endogenous miRNA
expression in the eye. (b) Expression levels of RDH10 and VAMP3,
two direct targets of miR-124 in retinas injected with high doses of
AAV2/5-CMV-EGFP-4xmR124T animals (n=4). The contralat-
eral eyes injected with the AAV2/5-CMV-EGFP control were
used as reference. ACTB and HPRT were used as internal controls.
Subretinal administration of AAV vectors harboring miRTs does
not detectably perturb endogenous miRNA activity in the eye.
Error bars represent the mean plus or minus SEM.
(TIF)
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